Expression of survivin and its splice variants in gastric cancer
Expression of survivin and its splice variants in gastric cancer
复制标题
DOI：
10.1007/s11596-007-0411-8
复制
发表时间：
2007-08-01
影响因子：
--
通讯作者：
Liao Xiaofeng
中科院分区：
文献类型：
--
作者：
Cheng Zhengjiang;Hu Lihua;Liao Xiaofeng
采用Survivin变异体特异性实时定量RT-PCR方法分析其在53对肿瘤和癌旁组织中的表达，并采用免疫组化方法检测野生型Survivin蛋白的表达。结果显示，survivin mRNA和蛋白在胃癌及癌旁组织中均有表达。survivin-2B在癌旁组织中主要表达，而survivin-Delta Ex3在癌旁组织中更常见。survivin-2a在癌组织和癌旁组织中的阳性表达率均为100%，但与癌旁组织相比，survivin-2a在癌组织中的相对转录本表达水平没有显著升高。相关分析显示，survivin-2a mRNA的表达与total survivin的表达呈显著相关（r(s) = 0.4178, P = 0.0018），与survivin- delta EX3的表达呈负相关（r(s) = -0.4506, P = 0.0007）。这表明survivin-2a可能作为survivin-Delta EX3的拮抗剂。抗凋亡存活素异构体和非抗凋亡存活素异构体之间的平衡可能在肿瘤发生和肿瘤进展中起重要作用。分析survivin及其变异在肿瘤早期诊断和良恶性鉴别中具有重要的应用价值。
Survivin variants specific real time quantitative RT-PCR was developed to analyze their expression in 53 paired cancer and para-cancerous tissues, and the expression of the wild-type survivin protein was detected by immunohistochemistry. The results showed that survivin mRNA and protein were expressed in gastric cancer and para-cancerous tissues. The survivin-2B was dominantly expressed in para-cancerous tissues, whereas the survivin-Delta Ex3 was more frequently detected in cancer tissues. The positive rate of survivin-2a was 100% in both cancer and para-cancerous tissues, but its relative transcript expression level was not significantly increased in cancer tissues in comparison with para-cancerous tissues. The correlation analysis revealed that the expression of survivin-2a mRNA was significantly associated with that of total survivin (r(s) = 0.4178, P = 0.0018), whereas inversely to that of survivin-Delta EX3 (r(s) = -0.4506, P = 0.0007). It was suggested that survivin-2a may act as an antagonist of survivin-Delta EX3. The balance between antiapoptotic survivin iso-forms and nonantiapoptotic ones may play an important role in tumorigenesis and tumor progression. Promising value is hinted to analyze survivin and its variants in tumor early diagnosis and distinguishing malignant tumors from benign ones.